KalVista Pharmaceuticals, Inc. (KALV) Presents at Jefferies London Healthcare Conference 2025 Transcript
KalVista Pharmaceuticals, Inc. ( KALV ) Jefferies London Healthcare Conference 2025 November 19, 2025 8:30 AM EST Company Participants Benjamin Palleiko - CEO & Director Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Presentation Maurice Raycroft Jefferies LLC, Research Division Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies.
KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates
KalVista Pharmaceuticals, Inc. (KALV) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to a loss of $0.91 per share a year ago.
KalVista Pharmaceuticals, Inc. (KALV) Q1 2026 Earnings Call Transcript
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV ) Q1 2026 Earnings Call September 11, 2025 8:30 AM EDT Company Participants Ryan Baker - Head of Investor Relations Benjamin Palleiko - CEO & Director Nicole Sweeny - Chief Commercial Officer Brian Piekos - Chief Financial Officer Paul Audhya - Chief Medical Officer Conference Call Participants Stacy Ku - TD Cowen, Research Division Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Tazeen Ahmad - BofA Securities, Research Division Maurice Raycroft - Jefferies LLC, Research Division Will Soghikian - Leerink Partners LLC, Research Division Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Serge Belanger - Needham & Company, LLC, Research Division Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division Catherine Okoukoni - Citizens JMP Securities, LLC, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. Welcome to KalVista Pharmaceuticals operational update and First Fiscal Quarter Financial Results.
KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates
KalVista Pharmaceuticals, Inc. (KALV) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to a loss of $0.87 per share a year ago.
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?
KalVista jumps 36% in a week after the FDA clears Ekterly, the first oral on-demand therapy for hereditary angioedema.
US FDA approves KalVista Pharma's swelling disorder drug
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug for a type of hereditary swelling disorder, sending its shares up 33.3% in premarket trading.
KalVista: Poised For Rare Disease Transformation
KalVista's lead asset, sebetralstat, is nearing FDA approval, targeting hereditary angioedema with a first-in-class oral treatment, presenting a significant market opportunity. Strong financial position with $253.2 million in cash, bolstered by $160 million in recent financing, ensures readiness for commercialization. Strategic partnerships, including a licensing deal with Kaken Pharmaceutical in Japan, and successful pediatric trial progress, de-risk and expand market potential.
Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch
KalVista Pharmaceuticals develops oral small-molecule therapies for hereditary angioedema targeting plasma kallikrein and Factor XIIa. Sebetralstat completed Phase 3 trials and submitted an NDA in June 2024. The company targets 2025 US, EU, UK, and Japan launches. KalVista raised $150.1 million in February 2024, securing a cash runway approximately 2.2 years after the raise.
